The application and research progress of anti-angiogenesis therapy in tumor immunotherapy

Front Immunol. 2023 Jun 2:14:1198972. doi: 10.3389/fimmu.2023.1198972. eCollection 2023.

Abstract

Tumor immunotherapy, as the focus of scientific research and clinical tumor treatment in recent years, has received extensive attention. Due to its remarkable curative effect and fewer side effects than traditional treatments, it has significant clinical benefits for the treatment of various advanced cancers and can improve cancer patient survival in the long term. Currently, most patients cannot benefit from immunotherapy, and some patients may experience tumor recurrence and drug resistance even if they achieve remission overcome. Numerous studies have shown that the abnormal angiogenesis state of tumors can lead to immunosuppressive tumor microenvironment, which affects the efficacy of immunotherapy. Actually, to improve the efficacy of immunotherapy, the application of anti-angiogenesis drugs to normalize abnormal tumor vessel has been widely confirmed in basic and clinical research. This review not only discusses the risk factors, mechanisms, and effects of abnormal and normalized tumor angiogenesis state on the immune environment, but summarizes the latest progress of immunotherapy combined with anti-angiogenic therapy. We hope this review provides an applied reference for anti-angiogenesis drugs and synergistic immunotherapy therapy.

Keywords: anti-angiogenesis therapy; immunotherapy resistance; tumor immunotherapy; tumor microenvironment; vascular normalization.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Humans
  • Immunotherapy
  • Neoplasms* / pathology
  • Neovascularization, Pathologic
  • Tumor Microenvironment

Substances

  • Angiogenesis Inhibitors

Grants and funding

This work was supported by the State Key Program of National Natural Science Foundation of China (grant number: 82130092) and the Innovative Capacity Building Project of the Hubei Engineering Research Center for Radiotherapy and Radiation Protection of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (grant number: 2018- 420114-35-03-071705).